Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin TherapySecondary Analysis From the FOURIER Randomized Clinical Trial

Prakash Deedwania, MD; Sabina A. Murphy, MPH; Andre Scheen, MD; et al.

doi : 10.1001/jamacardio.2020.3151

JAMA Cardiol. 2021;6(2):139-147

Importance  The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER randomized clinical trial. Patients with metabolic syndrome (MetS) are at increased cardiovascular risk.

خرید پکیج و مشاهده آنلاین مقاله

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesA Meta-analysis

Darren K. McGuire, MD, MHSc; Weichung J. Shih, PhD; Francesco Cosentino, MD, PhD; et al

doi : 10.1001/jamacardio.2020.4511

JAMA Cardiol. 2021;6(2):148-158

Importance  Sodium-glucose cotransporter 2 (SGLT2) inhibitors favorably affect cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the class remains uncertain.

خرید پکیج و مشاهده آنلاین مقاله

Evolving Trends in Adult Heart Transplant With the 2018 Heart Allocation Policy Change

Arman Kilic, MD; Michael A. Mathier, MD; Gavin W. Hickey, MD; et al.

doi : 10.1001/jamacardio.2020.4909

JAMA Cardiol. 2021;6(2):159-167

Importance  The US heart allocation policy was changed on October 18, 2018. The association of this change with recipient and donor selection and outcomes remains to be elucidated.

خرید پکیج و مشاهده آنلاین مقاله

Evaluation of Risk-Adjusted Home Time After Hospitalization for Heart Failure as a Potential Hospital Performance Metric

Ambarish Pandey, MD, MSCS; Neil Keshvani, MD; Mary S. Vaughan-Sarrazin, PhD; et al.

doi : 10.1001/jamacardio.2020.4928

JAMA Cardiol. 2021;6(2):169-176

Importance  Thirty-day home time, defined as time spent alive and out of a hospital or facility, is a novel, patient-centered performance metric that incorporates readmission and mortality.

خرید پکیج و مشاهده آنلاین مقاله

Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease

Ezimamaka Ajufo, BM, BCh; Colby R. Ayers, MS; Rebecca Vigen, MD, MSCS; et al.

doi : 10.1001/jamacardio.2020.4939

JAMA Cardiol. 2021;6(2):179-187

Importance  Higher coronary artery calcium (CAC) identifies individuals at increased atherosclerotic cardiovascular disease (ASCVD) risk. Whether it can also identify individuals likely to derive net benefit from aspirin therapy is unclear.

خرید پکیج و مشاهده آنلاین مقاله

Association of Echocardiographic Left Ventricular End-Systolic Volume and Volume-Derived Ejection Fraction With Outcome in Asymptomatic Chronic Aortic Regurgitation

Li-Tan Yang, MD; Vidhu Anand, MBBS; Elena I. Zambito, RDCS; et al.

doi : 10.1001/jamacardio.2020.5268

JAMA Cardiol. 2021;6(2):189-198

Importance  Volumetric measurements by transthoracic echocardiogram may better reflect left ventricular (LV) remodeling than conventional linear LV dimensions. However, the association of LV volumes with mortality in patients with chronic hemodynamically significant aortic regurgitation (AR) is unknown.

خرید پکیج و مشاهده آنلاین مقاله

Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency DepartmentA Randomized Clinical Trial

Sean P. Collins, MD, MSc; Dandan Liu, PhD; Cathy A. Jenkins, MSc; et al.

doi : 10.1001/jamacardio.2020.5763

JAMA Cardiol. 2021;6(2):200-208

Importance  Up to 20% of patients who present to the emergency department (ED) with acute heart failure (AHF) are discharged without hospitalization. Compared with rates in hospitalized patients, readmission and mortality are worse for ED patients.

خرید پکیج و مشاهده آنلاین مقاله

Effect of Clopidogrel and Aspirin vs Aspirin Alone on Migraine Headaches After Transcatheter Atrial Septal Defect ClosureOne-Year Results of the CANOA Randomized Clinical Trial

Jérôme Wintzer-Wehekind, MD; Eric Horlick, MD; Reda Ibrahim, MD; et al.

doi : 10.1001/jamacardio.2020.4297

JAMA Cardiol. 2021;6(2):209-213

Importance  Adding clopidogrel to aspirin for 3 months after transcatheter atrial septal defect (ASD) closure results in a lower incidence of new-onset migraine attacks. However, the outcomes at 6- to 12-month follow-up (after clopidogrel cessation at 3 months) remain largely unknown.

خرید پکیج و مشاهده آنلاین مقاله

Association of Subclinical Heart Maladaptation With the Pooled Cohort Equations to Prevent Heart Failure Risk Score for Incident Heart Failure

Nicholas Cauwenberghs, PhD; Francois Haddad, MD; Tatiana Kuznetsova, MD, PhD

doi : 10.1001/jamacardio.2020.5599

JAMA Cardiol. 2021;6(2):214-218

Importance  The Pooled Cohort Equations to Prevent Heart Failure (PCP-HF) estimate the 10-year risk for symptomatic heart failure (HF) from routine clinical data. The PCP-HF score should detect asymptomatic individuals with cardiac maladaptation preceding HF symptoms for it to be a useful HF prediction tool in primary prevention.

خرید پکیج و مشاهده آنلاین مقاله

Associations of Trabecular and Cortical Volumetric Bone Mineral Density With Coronary Artery Calcification ScoreThe Swedish Cardiopulmonary Bioimage Study Pilot Study

Thomas Funck-Brentano, MD, PhD; Louise Grahnemo, PhD; Ola Hjelmgren, MD, PhD; et al.

doi : 10.1001/jamacardio.2020.4880

JAMA Cardiol. 2021;6(2):238-240

The link between osteoporosis and cardiovascular diseases has been extensively reported, and previous studies show an inverse association between trabecular bone volumetric bone mineral density (Tb.vBMD) in the spine and coronary artery calcification score (CACS).1,2 However, the association between cortical vBMD (Ct.vBMD) in the long bones and CACS may differ from the association for Tb.vBMD because the 2 bone compartments are largely differentially regulated.3

خرید پکیج و مشاهده آنلاین مقاله

Mis-GUIDED—The Importance of Negative Trials of Health Care Delivery and Implementation Science

Larry A. Allen, MD, MHS; Colleen K. McIlvennan, PhD, DNP, ANP

doi : 10.1001/jamacardio.2020.5778

JAMA Cardiol. 2021;6(2):135-136

Modern medicine is a glittering edifice of possibilities. But it has also become a house of cards. For the average patient, who has multiple chronic conditions playing out among a host of psychological and socioeconomic issues, navigating the health care system is challenging. For clinicians and institutions, designing and executing complex care plans has also become challenging. As a result, many patients do not receive most of the potential benefits that health care has to offer. Unfortunately, some of these missed opportunities result in recurrent decompensations of chronic illnesses, such as heart failure (HF).

خرید پکیج و مشاهده آنلاین مقاله

Return to Play for Athletes After Coronavirus Disease 2019 Infection—Making High-Stakes Recommendations as Data Evolve

James E. Udelson, MD; Michael A. Curtis, MEd, CSCS; Ethan J. Rowin, MD

doi : 10.1001/jamacardio.2020.5896

JAMA Cardiol. 2021;6(2):136-138

As the coronavirus disease 2019 (COVID-19) pandemic began to evolve, case reports suggested that a clinical syndrome consistent with inflammatory myocarditis could occur as the underlying mechanism for the oft-seen elevations in biomarkers of myocardial injury and stress.1 However, as data have progressed, a picture has emerged from autopsy studies of myocardial involvement with viral infection and a cytokine response, but less often inflammatory cell infiltrate consistent with myocarditis.2 In July, a high-profile report3 emerged from Germany showing that more than 2 months after COVID-19 diagnosis, in a group of patients who had clinically recovered after a broad spectrum of disease severity (ranging from asymptomatic to severe illness with intubation), cardiac magnetic resonance (CMR) imaging and biomarker findings in the recovery phase were consistent with active ongoing myocardial involvement and inflammation in 60% of patients.

خرید پکیج و مشاهده آنلاین مقاله

Incorporating Patient Preferences Into Hospital Quality Metrics for Heart Failure

Adam D. DeVore, MD, MHS; Karen E. Joynt Maddox, MD, MPH

doi : 10.1001/jamacardio.2020.4964

JAMA Cardiol. 2021;6(2):177-178

Medicare’s Hospital Readmissions Reduction Program (HRRP), enacted in 2010, levies payment reductions to hospitals with higher than expected readmission rates for acute myocardial infarction, heart failure (HF), and pneumonia. A number of critiques have been made of the HRRP, including that its constituent readmission measures fail to adequately account for the competing risk of mortality, fail to differentiate between a short vs long readmission, and inadequately account for differences in social and medical risk among hospitals.1

خرید پکیج و مشاهده آنلاین مقاله

Coronary Artery Calcium for Personalized Risk Management—A Second Chance for Aspirin in Primary Prevention?

Miguel Cainzos-Achirica, MD, MPH, PhD; Philip Greenland, MD

doi : 10.1001/jamacardio.2020.4961

JAMA Cardiol. 2021;6(2):187-188

Over the last 2 years, use of low-dose aspirin for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) has become one of the most debated topics in cardiology.1,2 Initial trials conducted between the 1980s and early 2000s suggested a significant benefit in a primary prevention population at high risk. However, with expanded use of statins and declining ASCVD rates in Western countries in the last 2 decades, the benefit of prophylactic aspirin became progressively less certain among individuals without established ASCVD. Three trials1,2 published in 2018 found no benefit or modest benefit with aspirin and raised concerns about the potential for net harm in populations at increased bleeding risk. Still, given some trial and updated meta-analytic evidence of modest reductions in nonfatal ASCVD events, the 2019 American College of Cardiology (ACC)/American Heart Association (AHA) primary prevention guideline acknowledged that aspirin could have a role in helping candidates who are adequately selected: individuals younger than 70 years at low risk of bleeding and highest risk of ASCVD events (class IIb).3

خرید پکیج و مشاهده آنلاین مقاله

Coronavirus Disease 2019 and the Athletic HeartEmerging Perspectives on Pathology, Risks, and Return to Play

Jonathan H. Kim, MD, MSc; Benjamin D. Levine, MD; Dermot Phelan, MD, PhD; et al.

doi : 10.1001/jamacardio.2020.5890

JAMA Cardiol. 2021;6(2):219-227

Importance  Cardiac injury with attendant negative prognostic implications is common among patients hospitalized with coronavirus disease 2019 (COVID-19) infection. Whether cardiac injury, including myocarditis, also occurs with asymptomatic or mild-severity COVID-19 infection is uncertain. There is an ongoing concern about COVID-19–associated cardiac pathology among athletes because myocarditis is an important cause of sudden cardiac death during exercise.

خرید پکیج و مشاهده آنلاین مقاله

Association of Adverse Childhood Experiences With Cardiovascular Disease Later in LifeA Review

Lucas C. Godoy, MD; Claudia Frankfurter, MD; Matthew Cooper, BSc; et al.

doi : 10.1001/jamacardio.2020.6050

JAMA Cardiol. 2021;6(2):228-235

Importance  Adverse childhood experiences (ACEs) are potentially harmful events that occur during childhood, spanning neglect, physical or sexual abuse, parental separation, or death, among others. At least 50% of the US adult population has experienced 1 or more ACEs before the age of 18 years, but in clinical practice, ACEs remain underrecognized. Adults who have experienced ACEs are at increased risk of developing health risk behaviors and, ultimately, cardiovascular disease (CVD). This review summarizes the evidence regarding the association of ACEs with CVD and the accompanying diagnostic and therapeutic approaches in the adult population.

خرید پکیج و مشاهده آنلاین مقاله

A Patient Presenting With a Viral Prodrome, Palpitations, Dizziness, and Heart Block

Andrew E. Noll, MD; Amila D. William, MD; Niraj Varma, MD, PhD

doi : 10.1001/jamacardio.2020.5926

JAMA Cardiol. 2021;6(2):236-237

A previously healthy young adult presented with 1 week of fatigue, palpitations, and dyspnea on exertion, preceded by fever, myalgias, sore throat, and cough. Emergency department evaluation noted a heart rate of 64 beats per minute, blood pressure of 173/90 mm Hg, and a temperature of 37.1 °C. An electrocardiogram showed a sinus rhythm with complete heart block (CHB) and a narrow QRS junctional escape at 65 beats per minute (Figure, A). Investigation revealed an erythrocyte sedimentation rate of 30 mm/h (normal limits, 0-15 mm/h) and a C-reactive protein level of 6.3 mg/dL (reference range, 0.0-1.0 mg/dL [to convert to milligrams per liter, multiply by 10.0]). Tests for kidney function, hepatic function, a complete blood cell count, troponin T levels, creatine kinase levels, thyrotropin levels, antinuclear antibodies, and rheumatoid factor had normal results, and tests for anti–streptolysin O and anti–DNAse B titers, Lyme IgG and IgM titers, Coxiella burnetti and Bartonella serologies, Epstein-Barr virus serology, and cytomegalovirus quantification had negative results. A transthoracic echocardiogram showed no structural abnormalities, while fluorine 18–labeledfluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET–CT) showed a small focal area of FDG uptake in the region of the membranous septum (Figure, B). Systemic FDG uptake was absent. A CT showed no hilar adenopathy or pulmonary parenchymal abnormalities. Over the next 48 hours, the patient’s junctional rhythm accelerated to 90 beats per minute with ventriculoatrial block before acutely degenerating to a narrow complex escape rhythm of 45 beats per minutes associated with lightheadedness (Figure, C).

خرید پکیج و مشاهده آنلاین مقاله

A Patient With Congenital Heart Disease, Presenting With Angina

Marta Peverelli, MD; Ashwin Reddy, MA, MB BChir; Marina L. Hughes, DPhil

doi : 10.1001/jamacardio.2020.6940

JAMA Cardiol. 2021;6(2):e206940

What is the reason for angina in this patient with a functionally single ventricle (Figure)? A patient in their 40s with background situs inversus, a functionally single ventricle with large ventricular septal defect, and transposed great arteries presented with chest pain and breathlessness. Surgery in childhood involved bilateral Blalock-Taussig shunts and pulmonary artery banding, performed via thoracotomies. Computed tomography coronary angiography showed proximal occlusion of a large coronary artery branch (Figure, A) and calcified masses within the epicardium with extrinsic compression of the anterior coronary artery. Magnetic resonance imaging showed features consistent with a completed infarct (Figure, B; Video), and tissue characterization favoured classification as a fibroma, myofibroma, or tuberculoma. Heart failure treatment and anticoagulation (given a high risk of apical thrombus) were implemented.

خرید پکیج و مشاهده آنلاین مقاله

Right Ventricular Pressure–Volume Analysis Before and After Transcatheter Leaflet Approximation for Severe Mitral Regurgitation

Michael I. Brener, MD; Daniel Burkhoff, MD, PhD; Mohammad Sarraf, MD

doi : 10.1001/jamacardio.2020.7209

JAMA Cardiol. 2021;6(2):e207209

What is the right ventricular response to transcatheter edge-to-edge repair for mitral regurgitation? Biventricular pressure-volume (PV) analysis was performed with a conductance catheter (CD Leycom) in a patient in their 80s with severe primary mitral regurgitation (MR), before and after transcatheter leaflet approximation (Figure). MitraClip deployment resulted in decreased left atrial pressure (LAP) (24 to 16 mm Hg) and V-wave amplitude (47 to 21 mm Hg). The RV PV loops illustrate a marked reduction in afterload, or effective arterial elastance (Ea), which is represented by the slope of the dashed line connecting end-diastolic volume with the end-systolic PV point. When indexing RV Ea in this manner,1 Ea reflects both pulmonary arterial properties and LAP. MitraClip does not alter pulmonary arterial properties in the short term, but it did reduce LAP and V-wave amplitude dramatically in this patient. Consequently, RV Ea declined after MitraClip implantation, illustrating the pivotal role of left-sided filling pressures in RV afterload. This finding explains the observed improvements in RV function following transcatheter leaflet approximation2 and complements previous reports characterizing LV function after MitraClip implantation.3,4

خرید پکیج و مشاهده آنلاین مقاله

Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention

Sebastian J. Reinstadler, MD, PhD; Bernhard Metzler, MD, MSc; Gert Klug, MD

doi : 10.1001/jamacardio.2020.4753

JAMA Cardiol. 2021;6(2):240-241

To the Editor Recommendations on oral anticoagulation in patients with atrial fibrillation historically came from balancing the annual risk of cerebrovascular embolism (CHA2DS2-VASc score of 2, approximately 2%; CHA2DS2-VASc score of 4, approximately 4%) vs major bleeding (1.6% to 3.6%). The use of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention without atrial fibrillation is recommended based on randomized studies including more than 220?000 patients.1 Recently, trials on the use of double antithrombotic therapy (DAT) and triple antithrombotic therapy (TAT) in patients with both atrial fibrillation and the need for DAPT univocally demonstrated lower bleeding rates when using DAT compared with TAT. However, none of these trials was powered for efficacy regarding ischemic end points.

خرید پکیج و مشاهده آنلاین مقاله

Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention—Reply

Renato D. Lopes, MD, PhD; Amit N. Vora, MD, MPH; John H. Alexander, MD, MHS

doi : 10.1001/jamacardio.2020.4759

JAMA Cardiol. 2021;6(2):241

In Reply We appreciate the perspective of Reinstadler and colleagues regarding the optimal antithrombotic therapy strategy in patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI). To date, most regimens, guidelines, and clinical trials have started with the premise that oral anticoagulation (OAC) is necessary in the first month following PCI; to our knowledge, no study has evaluated dual antiplatelet therapy (DAPT) alone in this population.

خرید پکیج و مشاهده آنلاین مقاله

Patients With Severely Reduced Ejection Fraction Undergoing Revascularization—Is Something Missing?

Amy E. Cheney, MD; Ravi S. Hira, MD

doi : 10.1001/jamacardio.2020.4873

JAMA Cardiol. 2021;6(2):241-242

To the Editor Optimal revascularization of patients with multivessel coronary artery disease remains complex and controversial. With improved prevention and life expectancy, patients are presenting later in life with more comorbidities, chief among which is heart failure. The study by Sun et al1 contributes to our understanding but lacks discussion of contemporary percutaneous coronary intervention (PCI) techniques and complete revascularization.

خرید پکیج و مشاهده آنلاین مقاله

Patients With Severely Reduced Ejection Fraction Undergoing Revascularization—Is Something Missing?—Reply

Louise Y. Sun, MD, SM; Mario Gaudino, MD; Marc Ruel, MD, MPH

doi : 10.1001/jamacardio.2020.4887

JAMA Cardiol. 2021;6(2):242

In Reply We thank JAMA Cardiology for the opportunity to respond to the comments provided by Cheney and Hira. We appreciate their interest in our article.1

خرید پکیج و مشاهده آنلاین مقاله

Cardiac Involvement After Recovering From COVID-19

?ukasz A. Ma?ek, MD, PhD

doi : 10.1001/jamacardio.2020.5276

JAMA Cardiol. 2021;6(2):243

To the Editor I read with interest the article by Puntmann et al1 regarding the cardiac magnetic resonance (CMR) imaging findings in a group of 100 patients with asymptomatic to a severe course of coronavirus disease 2019 (COVID-19) after a median of 2 to 3 months from diagnosis. I was surprised by the high frequency of cardiac involvement still present in that group, including signs of fibrosis in 78% of patients and ongoing inflammation in 60% of them. The study drew large media attention around the world and brings serious clinical concerns regarding the potential need for in-depth cardiologic screening in all patients after recovering from COVID-19.

خرید پکیج و مشاهده آنلاین مقاله

Cardiac Involvement After Recovering From COVID-19

Laura Filippetti, MD; Nathalie Pace, MD; Pierre-Yves Marie, MD, PhD

doi : 10.1001/jamacardio.2020.5279

JAMA Cardiol. 2021;6(2):243-244

To the Editor We read with great interest the article by Puntmann et al1 on a cohort of German patients affected by coronavirus disease 2019 (COVID-19) and investigated by cardiovascular magnetic resonance (CMR) imaging. The authors’ observations are very similar to our own findings from a region of eastern France that was also severely affected by COVID-19. However, the interpretation of the results by Puntmann et al,1 particularly concerning the potential long-term persistence of myocardial inflammation, seems very alarmist, and in any case excessive, given the current state of understanding.

خرید پکیج و مشاهده آنلاین مقاله

Cardiac Involvement After Recovering From COVID-19—Reply

Valentina Puntmann, MD, PhD; Eike Nagel, MD

doi : 10.1001/jamacardio.2020.5285

JAMA Cardiol. 2021;6(2):244-245.

In Reply As the awareness about the numerous late effects of coronavirus disease 2019 (COVID-19) infection is taking hold, there is a growing understanding that cardiac involvement constitutes an important part of early and late stages of the COVID-19 illness. We recently demonstrated high prevalence of cardiac inflammation by cardiac magnetic resonance imaging in patients recovered from COVID-19 illness, with no trend of abating with the time passed from the acute COVID-19 illness.1 We emphasized the absence of longitudinal studies and hard outcome data, precluding any speculation on the long-term effects of these findings and indicated the need for more research. Yet in some parts of the press and by Filippetti et al, our findings have been described as “alarmist.” Filippetti et al suggest that the results of myocardial biopsies did not meet the criteria for true myocarditis, as used by Lindner et al.2 Notably, Lindner et al2 and our article1 both used the established pathological definitions by the World Health Organization and International Society and Federation of Cardiology.3 Whereas there was evidence of acute lymphocytic infiltration in myocardial biopsies months after the infection in our study,1 this was not the feature in patients who died during the acute illness.2 In our view, these findings are informative and complementary; cardiovascular damage and heart failure during the acute COVID-19 illness may result from exertion through febrile status, tachycardias, and general hypoxia, especially in those with preexisting cardiovascular conditions. However, later stages reveal intrinsic inflammatory myocardial involvement, accompanied by clinical manifestation of chronic fatigue and palpitations, thus explaining the different patterns in myocardial biopsies.

خرید پکیج و مشاهده آنلاین مقاله

Organ Acceptance and Outcomes—A Surgeon’s Perspective

Kathryn E. Engelhardt, MD, MS; Sameer Hirji, MD, MPH; Muhammad F. Masood, MD

doi : 10.1001/jamacardio.2020.5932

JAMA Cardiol. 2021;6(2):245

To the Editor We read with great interest the analysis of US National Transplant Registry data by Choi et al.1 This sophisticated analysis showed higher facility-level organ offer acceptance rates were associated with lower waitlist mortality, which is not surprising since the logical result of a high acceptance rate is fewer people waiting on the waitlist. Additionally, posttransplant mortality was equivalent among first-rank vs lower-rank offers, indicating, they concluded, that outcomes would be the same regardless of who accepted the organ. The findings are timely considering current revisions in United Network for Organ Sharing allocation and provide an avenue for further efforts to reduce waitlist mortality and improve overall transplant outcomes.

خرید پکیج و مشاهده آنلاین مقاله

Organ Acceptance and Outcomes—A Surgeon’s Perspective—Reply

Ashley Y. Choi, MHS; Hui-Jie Lee, PhD; Matthew G. Hartwig, MD

doi : 10.1001/jamacardio.2020.5935

JAMA Cardiol. 2021;6(2):245-246

In Reply Briefly, we examined variability in acceptance rates of heart offers made to the highest-priority candidates on the waitlist and its association with waitlist mortality. These rates varied considerably among centers, and every 10% increase in adjusted first-rank offer acceptance rate was associated with a 27% reduction in the rate of waitlist mortality, without detriment in 5-year adjusted posttransplant patient survival or graft failure.1

خرید پکیج و مشاهده آنلاین مقاله

United Network for Organ Sharing 2018 Heart Transplant Reallocation PolicyAiming for Evidence-Based Policy

Clyde W. Yancy, MD, MSc; Gregg C. Fonarow, MD

doi : 10.1001/jamacardio.2020.5232

JAMA Cardiol. 2021;6(2):168.

As editors of JAMA Cardiology, we greatly respect seeking the truth, endorsing benefits, and avoiding harms. These tenets are relatively straightforward to pursue for pharmacological therapies, devices, and interventional procedures. However, health policy creates new challenges and, in the case of the 2018 United Network for Organ Sharing (UNOS) heart transplant allocation policy, new concerns. It is out of our concerns of unintended consequences that we once again both publish and opine on the early experiences with this new policy.

خرید پکیج و مشاهده آنلاین مقاله

Left Ventricular End-Systolic Volume in Chronic Aortic Regurgitation—Finally, a Step Forward

Robert O. Bonow, MD, MS; Patrick T. O’Gara, MD

doi : 10.1001/jamacardio.2020.5282

JAMA Cardiol. 2021;6(2):199

Left ventricular (LV) dilation and systolic function are important determinants of outcome in patients with chronic aortic regurgitation. Left ventricular end-systolic dimension (LVESD) is a particularly useful measure because it incorporates components of both systolic function and volume overload and has been associated with clinical outcomes in patients who are asymptomatic. Recommendations for aortic valve replacement (AVR) in patients without symptoms based on LVESD (and indexed LVESD [LVESDi]) thresholds have been imbedded in US and European guidelines since 1998. However, these recommendations stem from decades-old natural history studies conducted when only M-mode measurements were available. Linear measurements of LV dimensions provide imprecise estimates of LV volumes, given the variable effects of volume overload on LV shape. It is also unclear where in a remodeled LV the short-axis dimensions should be routinely measured.

خرید پکیج و مشاهده آنلاین مقاله

Error in Methods and Table

doi : 10.1001/jamacardio.2020.6442

JAMA Cardiol. 2021;6(2):246

The Original Investigation “Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: a Subanalysis of the COMPASS Randomized Clinical Trial,”1 published September 30, 2020, contained an error in the Methods section. The sentence listing “(1) 2.5 mg of rivaroxaban twice daily plus 81 mg of aspirin once per day…and (3) 81 mg of aspirin once per day” should instead have noted 100 mg of aspirin in each of the locations it is mentioned. The same values appear in the headings of Table 1, where 81 mg should again have been 100 mg. This article was corrected online.

خرید پکیج و مشاهده آنلاین مقاله

Error in Author Degree

doi : 10.1001/jamacardio.2020.6736

JAMA Cardiol. 2021;6(2):246

The Original Investigation “Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease,”1 published October 28, 2020, contained an error in the author byline. Dr Ajufo’s name and degrees should be listed as “Ezimamaka Ajufo, BM, BCh.” This article was corrected online.

خرید پکیج و مشاهده آنلاین مقاله

Errors in Figure 3 and Supplement

doi : 10.1001/jamacardio.2020.6956

JAMA Cardiol. 2021;6(2):246

The Original Investigation “Associations of Adiposity, Circulating Protein Biomarkers, and Risk of Major Vascular Diseases,”1 published online December 2, 2020, contained errors with respect to the Supplement and Figure 3. eTables 12 and 13 and eFigures 19 and 20 in the Supplement were not mentioned in the main article text. The mentions have been added. In addition, Figure 3 in the article was altered to shorten vertical dotted lines, the length of which may have led to reader confusion. The article has been corrected online.

خرید پکیج و مشاهده آنلاین مقاله

Errors in Figure

doi : 10.1001/jamacardio.2020.6753

JAMA Cardiol. 2021;6(2):246

In the Brief Report titled, “Association of Subclinical Heart Maladaptation With the Pooled Cohort Equations to Prevent Heart Failure Risk Score for Incident Heart Failure,”1 published online November 11, 2020, there were errors in Figure 2. In all 4 panels, odds ratio more than 1 should indicate increased rate of abnormality and odds ratio less than 1 should indicate decreased rate of abnormality. This article was corrected online.

خرید پکیج و مشاهده آنلاین مقاله

JAMA Cardiology

doi : 10.1001/jamacardio.2020.4534

JAMA Cardiol. 2021;6(2):134

Mission Statement:? JAMA Cardiology publishes exceptional original research, state-of-the-art reviews, and informative opinions that advance the science and practice of cardiology, enhance cardiovascular health, and inform health care policy. JAMA Cardiology is the definitive journal for clinical investigators, clinicians, and trainees in cardiovascular medicine worldwide. JAMA Cardiology focuses on all aspects of cardiovascular medicine, including epidemiology and prevention, diagnostic testing, interventional and pharmacologic therapeutics, translational research, health care policy and outcomes, and global health.

خرید پکیج و مشاهده آنلاین مقاله